Lonza’s Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next‑Generation Bispecific ADCs
- Multi-target license agreement grants Sidewinder access to Lonza’s clinically validated ADC platform
- Sidewinder’s pipeline of precision bispecific ADCs combined with Lonza’s clinically validated ADC platform will enable the development of first-in-class bispecific ADCs with enhanced tumor-cell internalization to treat solid tumor indications
Amsterdam, The Netherlands, and San Diego, CA, 7 January 2026 — Synaffix B.V. (“Synaffix”), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, and Sidewinder Therapeutics, a precision ADC therapeutics company with a pipeline of bispecific antibodies with enhanced tumor-cell specificity and internalization, today announced that they have entered into a multi-target licensing agreement to develop first-in-class bispecific ADC therapeutics to treat solid tumor indications.
